Zhejiang Orient Gene Biotech Co., Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CNY 376.05 million compared to CNY 4,746.23 million a year ago. Revenue was CNY 376.05 million compared to CNY 4,746.23 million a year ago.

Net loss was CNY 50.33 million compared to net income of CNY 2,066.68 million a year ago. Basic loss per share from continuing operations was CNY 0.25 compared to basic earnings per share from continuing operations of CNY 10.25 a year ago. Diluted loss per share from continuing operations was CNY 0.25 compared to diluted earnings per share from continuing operations of CNY 10.25 a year ago.